CC
ABBV icon

Climber Capital’s AbbVie ABBV Stock Holding History

Climber Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Sell
897
-1,855
-67% -$399K 0.14% 62
2026
Q1 		$598K Buy
2,752
+1,855
+207% +$411K 0.39% 52
2025
Q4 		$205K Buy
+897
New +$204K 0.13% 58

Other funds holding ABBV

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Climber Capital's ABBV Position: Q2 2026 in Review

Climber Capital reduced its AbbVie (ABBV) stake by 67% in Q2 2026, selling an estimated $399K and leaving 897 shares worth $225K. The position accounts for 0.14% of the portfolio, ranked #62.

Climber Capital first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. The position peaked at $598K in Q1 2026. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Climber Capital held 897 shares of AbbVie worth $225K as of Q2 2026.
  • Climber Capital sold 1,855 AbbVie shares in Q2 2026, an estimated $399K.
  • AbbVie made up 0.14% of Climber Capital's portfolio in Q2 2026, its #62 holding.
  • Climber Capital first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • Climber Capital's AbbVie position peaked at $598K in Q1 2026.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Climber Capital's 13F filing for Q2 2026, filed 22 Jul 2026.